UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ALBAUGH, LLC,
Petitioner

v.

BASF SE,
Patent Owner

Case No. PGR2026-00026
Patent No. 12,305,206

DECLARATION OF INGO MEINERS

I, Ingo Meiners, declare and state as follows.

1. My name is Ingo Meiners. I am over the age of twenty-one years, of sound mind, and competent in all respects to make this Declaration. I have personal knowledge of the facts stated herein, and if called upon to do so, I could and would competently testify hereto.

2. I am the R&D Group leader – Biology R&D / Weed Control at BASF Agricultural Solutions US LLC ("BASF"). I am based in BASF's Raleigh office at 26 Davis Drive, Research Triangle Park, North Carolina 27709.

3. In my role, I am responsible for research and development of herbicides to provide new and innovative weed control for farmers. I have held positions involving glufosinate and L-glufosinate for eight years, and I am familiar with BASF's herbicide research, including testing such as field and greenhouse testing.

4. I personally coordinated and technically led the greenhouse trials in Appendix A to BASF's Arguments and Remarks made in the Amendment filed during the prosecution of U.S. Patent No. 12,305,206 ("the '206 Patent"). These trials were conducted to evaluate the phytotoxicity of L-glufosinate ammonium. I am personally familiar with and understand the test results and data in Appendix A.

5. These greenhouse test results were originally submitted during the prosecution of the '206 Patent. Ex. 2001 at 313. Furthermore, this data was then

Patent Owner BASF SE
Exhibit 2033 - Page 2 of 3

submitted in my declaration during the prosecution of U.S. Patent Application 16/633,482. Ex. 2029.

6. Each of the testing treatments of LGA used in the greenhouse tests contained 26% of technical grade LGA, 33% of SLES, and 41% of water.

7. The LGA used in these experiments contained an enantiomeric excess (e.e.) of L-glufosinate of about 96%, corresponding to about 98% by weight L-glufosinate. Enantiomeric excess specifies the degree to which a sample contains one enantiomer in greater amounts than its mirror-image enantiomer, here D-glufosinate.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on May 26, 2026.

Ingo Meiners

Ingo Meiners

Patent Owner BASF SE
Exhibit 2033 - Page 3 of 3